VRPX: Virpax Pharmaceuticals, Inc. Stock

by  •  • Comments Off on VRPX: Virpax Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 3.63
Enterprise Value ($M) -5.51
Book Value ($M) 1.93
Book Value / Share 1.65
Price / Book 1.88
NCAV ($M) 1.93
NCAV / Share 1.65
Price / NCAV 1.88

Profitability (mra)
Return on Invested Capital (ROIC) -7.85
Return on Assets (ROA) -0.82
Return on Equity (ROE) -1.00

Liquidity (mrq)
Quick Ratio 1.25
Current Ratio 1.25

Balance Sheet (mrq) ($M)
Current Assets 9.63
Assets 9.63
Liabilities 7.69
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -16.94
Net Income -15.19

Cash Flow Statement (mra) ($M)
Cash From Operations -9.85
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-02 13G/A Sabby Management, Llc 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-26 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-12-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S
2023-05-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-26 2,384 5,244 45.46
2024-04-25 3,284 1,142 287.57
2024-04-24 697 115 606.09
2024-04-23 1,486 1,663 89.36
2024-04-22 1,214 2,550 47.61

(click for more detail)

Similar Companies
VINC – Vincerx Pharma, Inc. VIRI – Virios Therapeutics, Inc.
VKTX – Viking Therapeutics, Inc. VSTM – Verastem, Inc.
VTGN – Vistagen Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io